Ingredient Guide
Ashwagandha vs Rhodiola Rosea: Which Is Better for Stress, Energy, and Mood?
Two leading adaptogens compared - stress, energy, and mood, grounded in clinical evidence.
Written by Jessica Medson
Ashwagandha has stronger and more consistent human clinical evidence for managing chronic stress and lowering cortisol, while rhodiola rosea may offer faster-acting support for acute mental fatigue and energy under pressure. A 2025 meta-analysis of 15 ashwagandha trials found it significantly reduced Perceived Stress Scale scores by approximately 4.9 points (p=0.001) and serum cortisol by approximately 2.4 mcg/dL (p less than 0.0001). Rhodiola's strongest evidence centers on cognitive performance during acute fatigue, with some benefits appearing within days; for most people dealing with persistent everyday stress, ashwagandha is the better-supported choice, while rhodiola is the more targeted option for mental stamina and pre-performance situations.
What Is Ashwagandha?
Ashwagandha (Withania somnifera) is a small woody shrub native to India, the Middle East, and parts of North Africa. In Ayurvedic medicine it is classified as a rasayana - a category of herbal tonics used to support vitality, stamina, and longevity. The root is the primary medicinal part and is standardized commercially to withanolide content, typically ranging from 2.5% to 35% depending on the extract form.
Active compounds
The primary bioactive constituents are withanolides - steroidal lactones that are thought to modulate the hypothalamic-pituitary-adrenal (HPA) axis, supporting a more measured cortisol response to stress. Alkaloids, saponins, and iron-containing compounds contribute additional activity. Well-researched proprietary extracts include KSM-66 (root-only, 5% withanolides) and Sensoril (root and leaf blend, 10% withanolides).
Traditional and modern use
Ayurvedic tradition prescribed ashwagandha to support physical endurance, cognitive function, and resistance to stress. Modern research has focused on the same domains - particularly stress reduction, cortisol modulation, sleep quality, and athletic performance - using these standardized root extracts in randomized controlled trials.
What Is Rhodiola Rosea?
Rhodiola rosea (golden root, Arctic root) is a flowering plant native to cold, high-altitude regions of Europe, Asia, and the Arctic. Its root and rhizome have been used for centuries in Scandinavian, Russian, and Tibetan folk medicine to reduce fatigue, support endurance, and help the body adapt to harsh environments. The plant is classified as an adaptogen - a substance thought to support nonspecific resistance to physical and psychological stressors.
Active compounds
The key bioactives are rosavins (rosavin, rosin, rosarin) and salidroside (tyrosol glucoside). Standardized extracts typically contain 3% rosavins and 1% salidroside. Research suggests these compounds modulate heat shock protein expression (Hsp70), may support mitochondrial energy production, and influence monoamine neurotransmitter systems - particularly norepinephrine and serotonin - which may partly explain reported effects on mood, focus, and mental clarity.
Traditional and modern use
Traditional use emphasized physical endurance and resilience in challenging environments. Contemporary research has focused on stress-related fatigue, burnout, cognitive performance, and exercise capacity, primarily using the standardized SHR-5 extract in clinical trials.
How They Compare: Stress, Energy, and Mood
Stress response
Ashwagandha has the deeper and more consistent body of evidence for chronic stress reduction. In an 8-week double-blind RCT of 58 healthy adults, 600 mg/day of ashwagandha root extract significantly reduced Perceived Stress Scale (PSS) scores from 22.95 to 14.15 (p<0.001) and reduced serum cortisol from 16.12 to 10.86 mcg/dL (p<0.0001) compared to placebo.1 A separate 60-day RCT using 240 mg/day of a highly concentrated ashwagandha extract (standardized to 35% withanolides) in 60 adults found a 23% reduction in morning cortisol versus a 0.5% increase in placebo (p<0.001), along with a 41% reduction in Hamilton Anxiety Rating Scale scores.2 A 2025 meta-analysis synthesizing 15 randomized trials in 873 adults confirmed that ashwagandha significantly reduced PSS scores (by approximately 4.9 points, p=0.001) and serum cortisol (by approximately 2.4 mcg/dL, p<0.0001) compared to placebo.13
Rhodiola rosea shows promise for stress-related fatigue but the evidence base is more limited. A Phase III randomized, double-blind, placebo-controlled trial of SHR-5 extract (576 mg/day) in 60 subjects with stress-related fatigue found significant improvements in fatigue, stress, depression subscores, and quality of life after 28 days.12 An open-label multicenter trial of 400 mg/day rhodiola in 117 patients with burnout found clinically meaningful reductions in emotional exhaustion, fatigue, and tension after 12 weeks, with 89.7% showing at least minimal improvement - though the absence of a control group limits interpretation.7 A 2012 systematic review of 11 rhodiola clinical trials concluded that while several studies showed benefit, methodological limitations prevent definitive efficacy conclusions.6
Stress verdict: Ashwagandha has stronger, more consistent human evidence. Rhodiola's evidence for stress-related fatigue is promising but not yet as robust.
Energy and physical performance
Ashwagandha has demonstrated measurable effects on physical endurance. A 2020 meta-analysis of four trials (142 participants) found a statistically significant improvement in maximum oxygen uptake (VO2max) with ashwagandha supplementation (mean difference 3.00 mL/kg/min, 95% CI 0.18-5.82, p=0.04), though heterogeneity was high and evidence quality was rated as low.3
Rhodiola's energy-related evidence centers more on reducing perceived mental effort and cognitive fatigue. An RCT comparing two doses of SHR-5 extract showed significant improvements in capacity for mental work, attention, and mental fatigue at doses of 170 mg and 185 mg compared to placebo and a non-treatment control group.11 A 2023 literature review concluded that acute rhodiola dosing (approximately 200 mg, standardized to ~1% salidroside and ~3% rosavins) showed select benefits for cognitive endurance, though results across studies are inconsistent due to dosing variability and heterogeneous study designs.10 Notably, one well-designed RCT found no improvement - and slightly worse fatigue scores - in nursing students taking 364 mg rhodiola versus placebo over 42 days,9 illustrating that the evidence is not uniformly positive.
Energy verdict: Ashwagandha appears more reliable for physical stamina over weeks of use. Rhodiola may offer faster support for acute mental energy but results vary substantially across studies.
Mood
Neither adaptogen is established as a mood treatment. In a 12-week Phase II randomized trial comparing rhodiola rosea, sertraline (an antidepressant), and placebo in 57 adults with mild-to-moderate major depressive disorder, all three groups showed modest Hamilton Depression Rating Scale (HAM-D) reductions with no statistically significant differences between them (rhodiola -5.1, sertraline -8.2, placebo -4.6; p=0.79). Crucially, rhodiola produced significantly fewer adverse events than sertraline (30% vs 63.2%, p=0.012).8
Ashwagandha showed significant anxiolytic effects in the Lopresti 2019 RCT (41% HAM-A reduction vs 24% in placebo, p=0.040) and a near-significant reduction in DASS-21 scores,2 suggesting a meaningful effect on anxiety-related mood states. However, ashwagandha has not been tested as a standalone treatment for clinical depression in a head-to-head design.
Mood verdict: Both show modest, non-definitive signals. Rhodiola has direct comparative data against an antidepressant; ashwagandha has stronger anxiolytic evidence from RCTs.
Which Should You Choose?
The best choice depends on your primary goal and timeline.
Choose ashwagandha if your primary concern is persistent, chronic stress, elevated cortisol, disrupted sleep, or gradual physical endurance improvement. Its benefits build over 4-8 weeks of consistent use, making it well suited as a daily supplement for ongoing stress resilience.
Choose rhodiola if you need faster-acting support for mental fatigue, cognitive performance under pressure (an upcoming exam, demanding work period, or athletic event), or if you are managing burnout symptoms. Rhodiola may produce noticeable effects within days to two weeks.
Consider combining them if you face both chronic background stress and periods of acute cognitive demand. Their primary mechanisms are complementary - ashwagandha works primarily via HPA axis modulation and cortisol reduction, while rhodiola modulates energy metabolism, Hsp70 expression, and monoamine neurotransmitter systems. No published human RCTs exist specifically on their combination, but no known pharmacokinetic interactions have been reported at typical doses.
For anxiety specifically: Ashwagandha has stronger clinical evidence for anxiety reduction than rhodiola. Neither replaces professional mental health evaluation or treatment for clinical anxiety or depressive disorders.
Practical note: Look for standardized extracts (KSM-66 or Sensoril for ashwagandha; SHR-5 or a 3% rosavins/1% salidroside-standardized extract for rhodiola). Third-party tested products reduce the risk of contamination or mislabeling.
Safety, Side Effects, and Drug Interactions
Ashwagandha
At typical doses (300-600 mg/day), ashwagandha is generally well tolerated. Reported adverse effects include mild gastrointestinal upset, drowsiness at higher doses, and loose stools. More seriously, multiple published case reports document drug-induced liver injury (DILI) in people taking ashwagandha supplements. One case involved a 65-year-old woman who developed jaundice and cholestatic liver injury approximately two weeks after starting ashwagandha; liver function normalized over approximately five months after discontinuation.4 A case series using updated RUCAM causality scoring rated ashwagandha as a "probable" cause in two additional cases; at least one prior case progressed to acute liver failure requiring transplantation.5 The proposed mechanism involves withanolides potentially forming toxic DNA adducts under conditions of low glutathione. Stop use immediately and consult a doctor if you develop jaundice (yellowing of skin or eyes), dark urine, severe fatigue, nausea, or right upper abdominal pain.
Ashwagandha may enhance sedative effects of CNS depressants. It may also interact with thyroid medications (monitor thyroid levels) and immunosuppressants, and has reported activity on CYP450 enzymes. Avoid during pregnancy (traditional contraindication; may stimulate uterine contractions) and during breastfeeding.
Rhodiola Rosea
At clinical doses, rhodiola is generally well tolerated. Reported adverse effects include dry mouth, dizziness, dose-dependent agitation, and insomnia - particularly if taken in the evening due to its activating properties. In the 12-week rhodiola vs sertraline RCT, 30% of rhodiola participants reported adverse events, compared to 63.2% in the sertraline group and 16.7% in the placebo group.8
Use caution if taking antidepressants - particularly SSRIs or MAO inhibitors - due to potential serotonergic interactions. Avoid combining with stimulant medications. Rhodiola has insufficient safety data for use during pregnancy and breastfeeding; avoid unless directed by a healthcare provider.
Stop rhodiola and seek medical advice if you experience significant agitation, heart palpitations, or worsening anxiety.
Dosage Reference: Ashwagandha and Rhodiola Rosea
Doses used in human clinical research. Start at the lower end and adjust based on individual response and tolerance. Consult a healthcare provider before starting any supplement.
| Goal | Typical Dose | Timing | Notes |
|---|---|---|---|
| Ashwagandha - stress and cortisol reduction | 300-600 mg/day | With meals, once or twice daily | Use KSM-66 or Sensoril standardized extract; benefits typically emerge at 4-8 weeks of consistent use |
| Ashwagandha - physical performance (VO2max support) | 500-600 mg/day | Daily with meals; 30-60 min pre-exercise on training days | Meta-analysis supports modest improvement; evidence quality rated low; 8+ weeks needed |
| Rhodiola - acute mental energy and focus | 200-400 mg (single dose) | 30-60 min before a demanding cognitive task, in the morning | Use SHR-5 extract or standardized to 3% rosavins/1% salidroside; avoid late-day dosing - stimulating effect may disrupt sleep |
| Rhodiola - stress-related fatigue and burnout (sustained use) | 400-576 mg/day | Morning, with or without food | Phase III RCT used 576 mg/day SHR-5 over 28 days; open-label burnout trial used 400 mg/day over 12 weeks |
Doses shown reflect ranges studied in published human trials. Individual needs vary. Higher doses have not been shown to consistently outperform moderate doses and may increase risk of side effects.
Ashwagandha vs Rhodiola Rosea: Head-to-Head
Key factors for choosing between these two adaptogens, based on available clinical evidence.
| Factor | Ashwagandha | Rhodiola Rosea |
|---|---|---|
| Primary strength | Chronic stress, cortisol reduction, sleep quality | Acute mental fatigue, cognitive performance under pressure, burnout |
| Speed of onset | Gradual - benefits typically at 4-8 weeks | Relatively rapid - may appear within days to 2 weeks |
| Human evidence - stress | Strong: multiple RCTs + 2 meta-analyses; significant cortisol and PSS reductions | Moderate: one Phase III RCT + open-label trial; systematic review notes methodological limits |
| Human evidence - energy | Moderate: VO2max meta-analysis (4 trials; low evidence quality rating) | Moderate: cognitive performance RCTs; mixed results for physical performance |
| Human evidence - mood/anxiety | Strong for anxiety (41% HAM-A reduction in RCT) | Modest: non-significant depression trend vs sertraline; fewer side effects than SSRI |
| Typical dose | 300-600 mg/day standardized root extract (KSM-66 or Sensoril) | 200-576 mg/day (3% rosavins + 1% salidroside; SHR-5 extract) |
| Effect on cortisol | Significant reduction documented in multiple RCTs and a 2025 meta-analysis | Not a primary documented mechanism; limited cortisol-specific data |
| Key safety concern | Rare but documented hepatotoxicity (DILI case reports; monitor liver symptoms) | Stimulating effect - may cause insomnia or agitation; possible SSRI/MAOI interactions |
| Pregnancy | Avoid - traditional contraindication; potential uterine stimulation | Avoid - insufficient safety data |
Evidence tiers: Strong = multiple RCTs + meta-analysis with consistent findings. Moderate = at least one RCT with positive results but limited replication or mixed findings. This table does not constitute medical advice.
Frequently Asked Questions
Is ashwagandha or rhodiola rosea better for stress?
Ashwagandha has stronger and more consistent clinical evidence for managing chronic stress. A 2025 meta-analysis of 15 randomized trials found it significantly reduced both Perceived Stress Scale scores and serum cortisol compared to placebo. Rhodiola rosea has useful but more limited evidence - a Phase III RCT showed improvements over 28 days, but a 2012 systematic review noted methodological limitations across studies. For most people dealing with persistent, day-to-day stress, ashwagandha is the better-supported choice. Rhodiola may be the better option when stress shows up as acute mental fatigue or burnout.
Can I take ashwagandha and rhodiola rosea together?
Combining the two is commonly practiced, and no serious pharmacokinetic interactions have been documented. Their mechanisms are complementary: ashwagandha primarily modulates the HPA axis and supports cortisol balance, while rhodiola acts on energy metabolism, stress proteins, and monoamine neurotransmitter systems. No published human RCTs exist specifically studying the combination. If you choose to combine them, start each individually to assess your personal tolerance before stacking, and use both at their standard doses.
Ashwagandha vs rhodiola rosea for anxiety - which is stronger?
Ashwagandha has stronger evidence for anxiety reduction. A 60-day RCT found it reduced Hamilton Anxiety Rating Scale (HAM-A) scores by 41% versus 24% in placebo (p=0.040), and a 2025 meta-analysis of 15 trials confirmed significant reductions in anxiety measures. Rhodiola's anxiety-specific evidence is less direct - it has shown benefits for stress-related fatigue but is not well studied as a dedicated anxiolytic in controlled trials. Neither adaptogen should replace professional evaluation or treatment for clinical anxiety disorder.
Ashwagandha vs rhodiola rosea for energy - which works faster?
Rhodiola rosea tends to act more quickly. Research suggests it can support mental energy and cognitive performance within days or even with a single dose before a demanding task. Ashwagandha's energy-related benefits - particularly for physical endurance and VO2max - tend to accumulate over 4-8 weeks of consistent use. Choose rhodiola if you need near-term support (before an exam, a demanding project, or an athletic event); choose ashwagandha if you are focused on building sustained physical stamina over time.
Is rhodiola rosea better than ashwagandha for focus and cognitive performance?
Rhodiola rosea has more directly targeted evidence in this area. Multiple trials using the SHR-5 extract show improvements in attention, mental work capacity, and cognitive performance under fatigue conditions. Ashwagandha's cognitive evidence is secondary - it reduces stress and anxiety, which can indirectly support cognitive function, but ashwagandha is not primarily studied as a cognitive enhancer. A 2012 systematic review of rhodiola trials noted methodological limitations, and one RCT in nursing students found no improvement. Overall, rhodiola is the more targeted choice specifically for mental focus under pressure.
What are the recommended doses for ashwagandha and rhodiola rosea?
For ashwagandha, most clinical trials used 300-600 mg/day of a standardized root extract (KSM-66 or Sensoril). For physical performance, some trials used up to 600 mg/day. For rhodiola, typical doses range from 200-576 mg/day of an extract standardized to 3% rosavins and 1% salidroside. For acute cognitive support, 200-400 mg taken 30-60 minutes before a demanding task is commonly studied. The Phase III stress-fatigue RCT used 576 mg/day SHR-5 extract over 28 days. Always start at the lower end of the range and do not exceed doses studied in published trials without medical guidance.
Are ashwagandha and rhodiola rosea safe for long-term use?
Most clinical trials for both herbs run 8-12 weeks and show acceptable safety profiles within that window. However, ashwagandha has documented rare but serious cases of drug-induced liver injury, and robust long-term safety data beyond 12 weeks is lacking for both herbs. Cycling either supplement (for example, 8-12 weeks on, 4 weeks off) is a common practice, though this pattern has not been specifically validated in clinical research. Consult a healthcare provider before long-term use, especially if you take any prescription medications or have underlying health conditions.
Ashwagandha vs rhodiola rosea for mood and depression - which is better?
The evidence is modest for both and neither is a validated treatment for clinical depression. Rhodiola rosea was compared directly to sertraline and placebo in a 12-week randomized trial in 57 adults with mild-to-moderate major depressive disorder - all three groups showed similar modest reductions in depression scores with no statistically significant differences between them. Rhodiola produced significantly fewer adverse events than sertraline. Ashwagandha shows stronger evidence for anxiety-related mood disturbance but has not been tested head-to-head against antidepressants. Neither adaptogen should replace professional care for moderate-to-severe depression.
Which is better for sleep - ashwagandha or rhodiola rosea?
Ashwagandha is the better-supported choice for sleep quality. An 8-week RCT found significant improvements in sleep quality at both 250 mg/day and 600 mg/day doses compared to placebo. Rhodiola, by contrast, has stimulating properties and may cause or worsen insomnia, particularly when taken in the afternoon or evening. It is generally recommended to take rhodiola in the morning only. If sleep quality is a primary concern, ashwagandha is the more appropriate option.
Who should avoid ashwagandha or rhodiola rosea?
Avoid ashwagandha if you are pregnant (traditional contraindication; possible uterine stimulation), have autoimmune conditions (it may further stimulate immune activity), take thyroid medications (it may alter thyroid hormone levels), or have a personal or family history of liver disease given documented hepatotoxicity cases. Use caution with sedatives, immunosuppressants, and drugs metabolized by CYP450 enzymes. Avoid rhodiola if you take SSRIs, MAO inhibitors, or stimulant medications due to potential serotonergic or stimulant interactions. Both should be avoided during pregnancy and breastfeeding due to insufficient safety data. Always consult a healthcare provider before starting either supplement.
Shop Ashwagandha vs Rhodiola
HealthFare Ashwagandha vs Rhodiola supplements
Scientific References
- ref-1.Salve J, Pate S, Debnath K, Langade D Adaptogenic and Anxiolytic Effects of Ashwagandha Root Extract in Healthy Adults: A Double-blind, Randomized, Placebo-controlled Clinical Study. Cureus. 2019. PubMed: 32021735Clinical (RCT / meta-analysis)
- ref-2.Lopresti AL, Smith SJ, Malvi H, Kodgule R An investigation into the stress-relieving and pharmacological actions of an ashwagandha (Withania somnifera) extract: A randomized, double-blind, placebo-controlled study. Medicine (Baltimore). 2019. PubMed: 31517876Clinical (RCT / meta-analysis)
- ref-3.Perez-Gomez J, Villafaina S, Adsuar JC, Merellano-Navarro E, Collado-Mateo D Effects of Ashwagandha (Withania somnifera) on VO2max: A Systematic Review and Meta-Analysis. Nutrients. 2020. PubMed: 32316411Clinical (RCT / meta-analysis)
- ref-4.Toth M, Benedek AE, Longerich T, Seitz HK Ashwagandha-induced acute liver injury: A case report. Clinical Case Reports. 2023. PubMed: 36937644Preclinical (animal / cell)
- ref-5.Bokan G, Glamocanin T, Mavija Z, Vidovic B, Stojanovic A, Bjornsson ES, Vucic V Herb-Induced Liver Injury by Ayurvedic Ashwagandha as Assessed for Causality by the Updated RUCAM: An Emerging Cause. Pharmaceuticals (Basel). 2023. PubMed: 37631044Preclinical (animal / cell)
- ref-6.Ishaque S, Shamseer L, Bukutu C, Vohra S Rhodiola rosea for physical and mental fatigue: a systematic review. BMC Complementary and Alternative Medicine. 2012. PubMed: 22643043Clinical (RCT / meta-analysis)
- ref-7.Kasper S, Dienel A Multicenter, open-label, exploratory clinical trial with Rhodiola rosea extract in patients suffering from burnout symptoms. Neuropsychiatric Disease and Treatment. 2017. PubMed: 28367055Human observational
- ref-8.Mao JJ, Xie SX, Zee J, Soeller I, Li QS, Rockwell K, Amsterdam JD Rhodiola rosea versus sertraline for major depressive disorder: A randomized placebo-controlled trial. Phytomedicine. 2015. PubMed: 25837277Clinical (RCT / meta-analysis)
- ref-9.Punja S, Shamseer L, Olson K, Vohra S Rhodiola Rosea for Mental and Physical Fatigue in Nursing Students: A Randomized Controlled Trial. PLoS One. 2014. PubMed: 25268730Clinical (RCT / meta-analysis)
- ref-10.Tinsley GM, Jagim AR, Potter GDM, Garner D, Galpin AJ Rhodiola rosea as an adaptogen to enhance exercise performance: a review of the literature. British Journal of Nutrition. 2023. PubMed: 37641937Human observational
- ref-11.Shevtsov VA et al. A randomized trial of two different doses of a SHR-5 Rhodiola rosea extract versus placebo and control of capacity for mental work. Phytomedicine. 2003. PubMed: 12725561Clinical (RCT / meta-analysis)
- ref-12.Olsson EMG et al. A randomised, double-blind, placebo-controlled, parallel-group study of the standardised extract SHR-5 of the roots of Rhodiola rosea in the treatment of subjects with stress-related fatigue. Planta Medica. 2009. PubMed: 19016404Clinical (RCT / meta-analysis)
- ref-13.Bachour G, Samir A, Haddad S, Houssaini MA, El Radad M Effects of Ashwagandha Supplements on Cortisol, Stress, and Anxiety Levels in Adults: A Systematic Review and Meta-Analysis. BJPsych Open. 2025. PubMed: PMC12242034Clinical (RCT / meta-analysis)